Puma Biotechnology is committed to sharing clinical trial data and information to help
physicians and patients make informed treatment decisions, and to help qualified
researchers advance scientific knowledge.
In accordance with legal and regulatory requirements, Puma publishes study protocol
information and clinical study results on clinical trial registries, including
ClinicalTrials.gov and EU Clinical Trials Register. Puma also publishes information
about clinical studies in peer-reviewed scientific journals and shares data in scientific
meetings.
Puma commits to safeguarding confidentiality and patient privacy throughout the clinical
trial data and information sharing process. Any patient-level data will be anonymized to
protect personally identifiable information. Puma will not provide access to patient-level
data if there is a reasonable likelihood that individual patients could be identified, or in
cases where confidentiality or consent provisions prohibit transfer of data or information
to third parties. Additionally, Puma will not disclose information that jeopardizes
intellectual property rights or divulges confidential commercial information.
Qualified researchers and study participants may submit requests for other study
documentation and clinical trial data to clinicaltrials@pumabiotechnology.com for
consideration.
2023
No new research proposals were submitted to the company.
2022
Two research proposals were submitted to the company.
- The first proposal was approved, a Data Sharing Agreement was executed, anonymized
individual datasets were prepared and delivered (efficacy data excluded). The research is
ongoing at the time of this update and is expected to conclude in 2024.
- The second proposal was approved with conditions, and later closed after no further
communication from the requestor. The study associated with this proposal is now outside of
the data sharing eligibility timeframe specified in our company policy.
Last updated on January 15, 2024
|
